11.16.11
Genzyme and Cystic Fibrosis Foundation Therapeutics, Inc. have entered a research agreement for the discovery of new drugs to treat the most common mutation found in patients with CF, Delta F508.
The companies will focus on identifying compounds known as “correctors,” which may help the malfunctioning CFTR protein found in CF patients to operate correctly. Researchers will evaluate different compounds for correctors for Delta F508 using compound libraries of both Genzyme and its parent company, Sanofi.
“We are delighted to enter into a research collaboration with Genzyme, a company that has long dedicated itself to improving the lives of people with rare diseases,” said Robert J. Beall, Ph.D., president and chief executive officer of the CF Foundation. “Genzyme’s capabilities and resources will help the CF Foundation accelerate its effort to find drugs to treat the most common mutation in CF and have the greatest impact on those with this disease.”
“While there has been great momentum recently in cystic fibrosis research, there is still great unmet need,” said Genzyme’s president and chief executive officer David Meeker, MD. “Together with the CF Foundation, we look forward to working to accelerate the pace of discovery on behalf of CF patients around the world.”
The companies will focus on identifying compounds known as “correctors,” which may help the malfunctioning CFTR protein found in CF patients to operate correctly. Researchers will evaluate different compounds for correctors for Delta F508 using compound libraries of both Genzyme and its parent company, Sanofi.
“We are delighted to enter into a research collaboration with Genzyme, a company that has long dedicated itself to improving the lives of people with rare diseases,” said Robert J. Beall, Ph.D., president and chief executive officer of the CF Foundation. “Genzyme’s capabilities and resources will help the CF Foundation accelerate its effort to find drugs to treat the most common mutation in CF and have the greatest impact on those with this disease.”
“While there has been great momentum recently in cystic fibrosis research, there is still great unmet need,” said Genzyme’s president and chief executive officer David Meeker, MD. “Together with the CF Foundation, we look forward to working to accelerate the pace of discovery on behalf of CF patients around the world.”